We expect Light & Wonder will continue to return capital to shareholders through share repurchases. Because repurchases can be flexed through any earnings volatility, we view this as a reasonable way ...

President Donald Trump will announce a plan to lower U.S. prescription drug costs by tying the amount the government pays for ...

Americans prioritize taste (83%) over cost (62%), healthiness (52%), and convenience (47%) when making food choices, though ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Following more than a month of negotiations between UK ministers and US officials, the UK has been granted a reprieve from ...

An investigation into everything Trump and his advisers have said about dolls, which is a lot more than anyone could have ...

The program is designed to offer clarity for manufacturers, procurement officials, and government agencies seeking products ...

A class action lawsuit has been filed in Texas against Toyota North America. The action claims Toyota unlawfully shared ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump ...

It has been over a decade since some Hong Kong manufacturers, responding to the mainland’s sweeping industrial upgrade and sensing rising US-China trade tensions, moved to set up factories overseas.

Pharmaceutical and Research Manufacturers of America (PhRMA) yesterday submitted comments to the US Department of Commerce on ...

The banning of pharmaceutical advertisements is not an assault on free speech. Big Pharma cannot be trusted with the health ...